Rejuvenate Biomed
Rejuvenate Biomed is an AI-enabled clinical-stage biotech company focused on discovering and developing combination drugs to promote healthy aging and impact multiple age-related diseases. Their pipeline includes RJx-01, currently in a Phase 2 clinical trial for COPD-related muscle weakness and sarcopenia. The company leverages AI tools for disease-agnostic drug repurposing to accelerate drug development. They are committed to sustainable development goals and have partnerships with institutions like NIHR Leicester BRC and Wellcome Leap. Rejuvenate Biomed operates from Belgium and the USA, targeting age-related disease therapeutics with a clinical and AI-driven approach.
Rejuvenate Biomed
Rejuvenate Biomed is an AI-enabled clinical-stage biotech company focused on discovering and developing combination drugs to promote healthy aging and impact multiple age-related diseases. Their pipeline includes RJx-01, currently in a Phase 2 clinical trial for COPD-related muscle weakness and sarcopenia. The company leverages AI tools for disease-agnostic drug repurposing to accelerate drug development. They are committed to sustainable development goals and have partnerships with institutions like NIHR Leicester BRC and Wellcome Leap. Rejuvenate Biomed operates from Belgium and the USA, targeting age-related disease therapeutics with a clinical and AI-driven approach.
TL;DR
Stage: Clinical-stage (Phase 2 for lead asset RJx-01)
Founded: 2017
Headquarters: Diepenbeek (Belgium); U.S. office in Cambridge, MA
Founder / CEO: Ann Beliën, PhD
Tech: AI-enabled drug discovery (CombinAge, CelegAge)
Recent funding: Series B (Oct 12, 2021) ~€15.7M
Company Overview
Problem Domain
Age-related diseases, healthy aging, sarcopenia, COPD-related muscle weakness
Founded
2017
Industry
Biotechnology
Tech Stack
Funding Track Record
€3.2 million
Included private and existing investors; VLAIO provided non-dilutive support.
€15.7 million
Rejuveron Life Sciences led the round; Vesalius Biocapital participated; Rejuveron became majority shareholder.
Investor Signal
“Rejuveron Life Sciences became majority shareholder following Series B; participation from Vesalius Biocapital indicates institutional VC backing.”